Literature DB >> 23175692

Unique dominant negative mutation in the N-terminal mitochondrial targeting sequence of StAR, causing a variant form of congenital lipoid adrenal hyperplasia.

María Sonia Baquedano1, Gabriela Guercio, Roxana Marino, Esperanza Berensztein, Mariana Costanzo, Marcela Bailez, Elisa Vaiani, Mercedes Maceiras, Pablo Ramirez, Eduardo Chaler, Marco A Rivarola, Alicia Belgorosky.   

Abstract

CONTEXT: Steroid acute regulatory (StAR) protein is a mitochondria-targeted protein that is part of the transduceosome complex crucial for transport of cholesterol to mitochondria. Recessive mutations cause classic and nonclassic congenital lipoid adrenal hyperplasia.
OBJECTIVE: The aim of this study was to report the clinical, hormonal, genetic, and functional data of a novel heterozygous mutation in the StAR gene found in a 46,XY patient with ambiguous genitalia and neonatal severe steroidogenic deficiency. PATIENT: Undetectable serum steroids with high ACTH and plasma renin activity but normal acute GnRH response were found in infancy. After gonadectomy (at 3 yr of age), serum LH and testosterone were undetectable, whereas FSH was normal but increased slowly afterward. Estrogen replacement therapy, started at 10.2 yr of age, suppressed gonadotropins (for 2 yr). However, after 1 month off estrogens, the patient showed castrated levels. At 11.9 yr old, after fludrocortisone withdrawal because of hypertension, plasma renin activity and aldosterone remained normal, suggesting mineralocorticoid recovery by a StAR-independent mechanism.
RESULTS: We found a de novo heterozygous IVS-2A>G StAR mutation and the reported heterozygous p.G146A SF1 polymorphism with normal CYP11A1, FDXR, FDX1, VDAC1, and TSPO genes. The mutant StAR transcript lacked exon 2, resulting in the in-frame loss of amino acids 22 to 59 in the N-terminal mitochondrial targeting signal. In vitro, the mutant protein exhibited reduced StAR activity in a dominant-negative manner and almost no mitochondria localization.
CONCLUSIONS: A misfolded p.G22_L59del StAR might interfere with wild-type StAR activity by blocking the transduceosome complex, causing an autosomal dominant form of StAR deficiency, explaining the clinical phenotype. We speculated that estrogen might have modulated mineralocorticoid function and pubertal maturation in a human natural model lacking endogenous steroid production.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23175692     DOI: 10.1210/jc.2012-2865

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  Congenital lipoid adrenal hyperplasia: Immunohistochemical study of testosterone synthesis in Leydig cells.

Authors:  Kanako Matsuoka; Yuichi Sato; Seiji Hoshi; Tomoyuki Koguchi; Soichiro Ogawa; Tomohiro Ishii; Nobuhiro Haga; Tomonobu Hasegawa; Yoshiyuki Kojima
Journal:  IJU Case Rep       Date:  2020-01-14

2.  WT1, NR0B1, NR5A1, LHX9, ZFP92, ZNF275, INSL3, and NRIP1 Genetic Variants in Patients with Premature Ovarian Insufficiency in a Mexican Cohort.

Authors:  Luis Ramos
Journal:  Genes (Basel)       Date:  2022-03-29       Impact factor: 4.141

3.  A Novel Intronic Pathogenic Variant in STAR With a Dominant Negative Mechanism Causes Attenuated Lipoid Congenital Adrenal Hyperplasia.

Authors:  Erin Finn; Kimberly Kripps; Christina Chambers; Michele Rapp; Naomi J L Meeks; Fang Xu; Wuyan Chen; Austin A Larson; Natalie J Nokoff
Journal:  J Investig Med High Impact Case Rep       Date:  2021 Jan-Dec

4.  Hybrid gel electrophoresis using skin fibroblasts to aid in diagnosing mitochondrial disease.

Authors:  Christopher Newell; Aneal Khan; David Sinasac; John Shoffner; Marisa W Friederich; Johan L K Van Hove; Stacey Hume; Jane Shearer; Iveta Sosova
Journal:  Neurol Genet       Date:  2019-05-01

Review 5.  Adrenal Mitochondria and Steroidogenesis: From Individual Proteins to Functional Protein Assemblies.

Authors:  Andrew Midzak; Vassilios Papadopoulos
Journal:  Front Endocrinol (Lausanne)       Date:  2016-07-29       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.